what happened to vp of sales?

Quote












TR was forced out. Sales were down and JD took the opportunity to start the beat-down on him. Those two were in some weird frat-boy type of competition with each other so JD used the shitty 1Q sales to take out his adversary. No brainer for TR to take a payout and move on before they fired him.
 












Anonymous said:
TR was forced out. Sales were down and JD took the opportunity to start the beat-down on him. Those two were in some weird frat-boy type of competition with each other so JD used the shitty 1Q sales to take out his adversary. No brainer for TR to take a payout and move on before they fired him.
Click to expand...

Thanks for the information. Would still like to know if a replacement for VP of sales will be made.
 












TR was better than RR. Surprised they would leave VP of sales position vacant for so long when sales are so poor. Probably hard to attract top notch talent at a comany that many seem to think is "terminal"
 
























Anonymous said:
TR was better than RR. Surprised they would leave VP of sales position vacant for so long when sales are so poor. Probably hard to attract top notch talent at a comany that many seem to think is "terminal"
Click to expand...

Retired. Went somewhere else. Whatever the case, the important position remains vacant and how many people would actually want the position at a company with a 500M market value, half of which is the company's cash holdings and 620M that has to be paid to bondholders in EARLY 2016. (may even be January 2016). Seems like a sinking ship.
 






European approval of provenge only weeks away, sales up 8% last quarter, strong sales uptake this quarter, immunotherapy the talk of ASCO 2013, provenge gaining wider acceptance among key medical opinion leaders, predictive treatment biomarkers on the way, sequencing-combo provenge clinical trials ongoing with read outs soon, studies for lable expansion, a successful national ad campaign, automated lower cost manufacturing for 2014, and a follow on product in the name of Neuvenge for bladder cancer and it becomes clear that the future of our company is bright.
 






Anonymous said:
Retired. Went somewhere else. Whatever the case, the important position remains vacant and how many people would actually want the position at a company with a 500M market value, half of which is the company's cash holdings and 620M that has to be paid to bondholders in EARLY 2016. (may even be January 2016). Seems like a sinking ship.
Click to expand...

Europe is a non starter too. Everyone knows Euro approval isn't far off and the company value stays in the 500M range. Doesn't seem like anyone truly talented would be interested in joining the ranks of a company that many are predicting an end of within the next 2 years. People usually prefer stability.
 






Anonymous said:
European approval of provenge only weeks away, sales up 8% last quarter, strong sales uptake this quarter, immunotherapy the talk of ASCO 2013, provenge gaining wider acceptance among key medical opinion leaders, predictive treatment biomarkers on the way, sequencing-combo provenge clinical trials ongoing with read outs soon, studies for lable expansion, a successful national ad campaign, automated lower cost manufacturing for 2014, and a follow on product in the name of Neuvenge for bladder cancer and it becomes clear that the future of our company is bright.
Click to expand...

Immunotherapy was not the talk of ASCO 2013. It was Radium as presented in our own symposia?
 






Anonymous said:
European approval of provenge only weeks away, sales up 8% last quarter, strong sales uptake this quarter, immunotherapy the talk of ASCO 2013, provenge gaining wider acceptance among key medical opinion leaders, predictive treatment biomarkers on the way, sequencing-combo provenge clinical trials ongoing with read outs soon, studies for lable expansion, a successful national ad campaign, automated lower cost manufacturing for 2014, and a follow on product in the name of Neuvenge for bladder cancer and it becomes clear that the future of our company is bright.
Click to expand...

That's why all the talent left a year ago......and things are so good they canned/retired the VP of sales (no replacement) shiffman left the CFO role and the few people left that have ANY clue what it takes to get a pt through the system are scurrying like rats off a sinking ship. All is well and looking up. Not to mention the massive cuts looming.....Your posts are just plain pathetic.
 






Anonymous said:
Immunotherapy was not the talk of ASCO 2013. It was Radium as presented in our own symposia?
Click to expand...

The sad part was the CME the first evening of ASCO in Chicago with the panel of 3 physicians. We had 3 senior dndn medical/marketing there. Think it was sartor, druker?, and another (cant remember) giving an overview to 300+ physicians about mCRPC therapies-sponsored by Dendreon. At the end there was a "audience participation test" of multiple choice answers. They went over Provenge extensively in the presentation and only 20-25% of the audience said they have used Provenge in its label. Even worse, 75% of the audience stated they would NEVER prescribe it due to cost/lack of measurable endpoints-zytiga, xtandi and radium were the preferred products. It's really sad current management thought they were so smart they could just contract Provenge to blockbuster status with 0 knowledge of the space. It's not supportive care (procrit, ep, etc.) but they refused to listen to anyone that tried to explain the complexicities of this product.

They are learning now though. Too bad because there are many men out there that could really benefit from this therapy but will never have the opportunity.

Good luck to all.....
 






Anonymous said:
Immunotherapy was not the talk of ASCO 2013. It was Radium as presented in our own symposia?
Click to expand...



ASCO 2013 Heralds New Era of Immunotherapy

“Immunotherapy against cancer was the talk of the day, both at the ASCO meeting itself and in the media”, says Dirk Groenewegen, CEO of Glycostem, who recently returned from a trip to the US, where he also visited the annual meeting of the American Society of Clinical Oncology (ASCO). The optimistic atmosphere at the ASCO meeting is a strong sign that not just scientists, but more and more clinicians, pharmaceutical companies and investors are convinced of the power of immunological approaches against cancer. Even Wall Street reacted: shares of large pharma companies involved in immunotherapy like Merck and Bristol Myers Squibb rose by several percent. Says Groenewegen: “There was an atmosphere of hope, that after many years of hardly any progress, we now witness the beginning of a new era, with the advent of effective immunotherapy. It is no longer just a dream, but a tangible reality”. In addition to immunotherapy based on monoclonal antibodies, several ASCO speakers presented positive results with cellular approaches to immunotherapy. Groenewegen explains why the good news about all kinds of immunotherapy are important to him: “Glycostem is of course originally and primarily involved in the production of cellular therapies, but we are developing ways to employ the synergy between antibodies and our NK cell product. In other words: good news for antibody-based immunotherapy is good news for us, too!”

http://www.glycostem.com/asco2013/
 






Anonymous said:
The sad part was the CME the first evening of ASCO in Chicago with the panel of 3 physicians. We had 3 senior dndn medical/marketing there. Think it was sartor, druker?, and another (cant remember) giving an overview to 300+ physicians about mCRPC therapies-sponsored by Dendreon. At the end there was a "audience participation test" of multiple choice answers. They went over Provenge extensively in the presentation and only 20-25% of the audience said they have used Provenge in its label. Even worse, 75% of the audience stated they would NEVER prescribe it due to cost/lack of measurable endpoints-zytiga, xtandi and radium were the preferred products. It's really sad current management thought they were so smart they could just contract Provenge to blockbuster status with 0 knowledge of the space. It's not supportive care (procrit, ep, etc.) but they refused to listen to anyone that tried to explain the complexicities of this product.

They are learning now though. Too bad because there are many men out there that could really benefit from this therapy but will never have the opportunity.

Good luck to all.....
Click to expand...

Thank you very much for your candid and truthful posts. They have been very helpful. It's nice to hear from someone who actually works for the company who tells the truth instead of a estee person who has no qualms about misleading people down the wrong path
 






Anonymous said:
European approval of provenge only weeks away, sales up 8% last quarter, strong sales uptake this quarter, immunotherapy the talk of ASCO 2013, provenge gaining wider acceptance among key medical opinion leaders, predictive treatment biomarkers on the way, sequencing-combo provenge clinical trials ongoing with read outs soon, studies for lable expansion, a successful national ad campaign, automated lower cost manufacturing for 2014, and a follow on product in the name of Neuvenge for bladder cancer and it becomes clear that the future of our company is bright.
Click to expand...

That outlines the positive long-term outlook very well. Provenge is definitely gaining broad market acceptance. The process just takes some time.
 












Top Bottom
Back
Quote